Md. Saqline Mostaq a former student of the Department of Pharmacy, University of Asia Pacific (UAP) and a current Ph.D. candidate in Molecular Cancer Biology at the University of Louisiana at Monroe, USA presented groundbreaking research at Research Day 2025, focusing on cancer drug resistance and p53 mutations. His findings include targeting Glucosylceramide Synthase, inhibiting GCS and identifying novel RNA modifications.
On February 28, 2025, Saqline presented his groundbreaking research at Research Day 2025, hosted by the Edward Via College of Osteopathic Medicine (VCOM), Monroe. His poster, titled “Inhibition of Glucosylceramide Synthase Reactivates p53-Suppressive Effects on Cancer Stem Cells through m6A Modification at p53 R273 Mutant Codon,” earned him the 2nd Runner-Up award in the Biomedical Research category, along with a certificate and research grant.
🔬 Research Highlights:
✅ Targeting Glucosylceramide Synthase (GCS) sensitizes p53 R273H-mutant cancer cells to chemotherapy.
✅ CRISPR-Cas9-mediated UGCG knockout (GCS inhibition) significantly reduces drug resistance, suppresses cancer stem cells, and decreases tumor growth.
✅ A groundbreaking connection between ceramide metabolism and m6A RNA modification was identified, uncovering a novel strategy to counteract drug resistance in p53-mutant cancers.
Under the mentorship of Dr. Yong-Yu Liu, Saqline is pioneering innovative solutions to overcome drug resistance in p53-mutant colon cancer, a major challenge in cancer treatment. His research holds immense promise for more effective therapies in the future.